Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study, demonstrating the benefit of Mim8 in 70 children (aged 1-11 years old) with hemophilia A, both with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment with the investigational drug, offering participants the option to switch to once-monthly dosing after 26 weeks.
Positive Trial Results
Mim8 was found to be well-tolerated and efficacious in children with hemophilia A, regardless of inhibitor status. At week 26, 98% of caregivers reported a preference for Mim8 over prior treatment, with 73% indicating they “very strongly” preferred Mim8. Additionally, significant improvements were observed in the mean physical function score and mean quality of life (QoL) total score compared to baseline, highlighting the drug’s potential to enhance daily activities and overall well-being in young patients.
About Mim8
Mim8 is a Factor VIIIa (FVIIIa) mimetic bispecific antibody (BsAb) designed to achieve sustained hemostasis for once-weekly, once every two weeks, or once-monthly prophylaxis in individuals with hemophilia A, both with and without inhibitors. The use of Mim8 in treating hemophilia A is still investigational and has not been approved by regulatory authorities or made available anywhere in the world.-Fineline Info & Tech
